Case Studies

Challenge An oncology-focused biopharma company needed support to develop a pipeline of kinase inhibitors in early- and late-stage development.

Challenge: A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic oncology candidates, while allowing prospective partners to access the...

Challenge An emerging drug discovery company, with a core expertise in molecular modelling, had developed a small molecule inhibitor for a novel cancer metabolism target. The company was looking to...

Challenge A mid-cap pharma company seeking to establish a biologics pipeline through partnership with a monoclonal antibody development boutique needed an assessment of target opportunities,...

Challenge A university in a developing country wanted advice on best practice for IP protection and technology transfer. Alacrita was engaged to develop a plan for provision of these services.A...

Challenge A start-up that had developed a suite of proprietary antibody technologies needed help to identify accessible cell surface proteins for discovery of candidate therapeutic monoclonal...

Challenge We have conducted multiple due diligence projects, below are three examples:

Challenge A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that...

Challenge The technology transfer function of a leading cancer research institute needed a development plan for a promising small molecule lead series against a novel anti-invasion/anti-metastasis...

Challenge A major public/private investor in a BRIC territory needed help with an investment strategy for building a nationwide radiopharmaceutical infrastructure and capacity in its home country....

Challenge A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Alacrita was engaged to help craft a new R&D strategy.

Challenge: Alacrita conducted an assessment of an AAV gene therapy for an ophthalmic indication, focusing on market potential, technical and regulatory issues and identification of key risks.